Detke Michael J. 4
4 · Cortexyme, Inc. · Filed Dec 15, 2020
Insider Transaction Report
Form 4
Cortexyme, Inc.CRTX
Detke Michael J.
Chief Medical Officer
Transactions
- Award
Stock Option (Right to Buy)
2020-12-11+100,000→ 100,000 totalExercise: $29.60Exp: 2030-12-10→ Common Stock (100,000 underlying) - Award
Stock Option (Right to Buy)
2020-12-11+100,000→ 100,000 totalExercise: $29.60Exp: 2030-12-10→ Common Stock (100,000 underlying)
Footnotes (2)
- [F1]The shares subject to the option vest in 48 equal monthly installments from the vesting commencement date, subject to the grantee's continuous service to the Issuer on each such date.
- [F2]50% of the shares will vest on March 31, 2023 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 1 (as defined below) has been met, and 50% of the shares will vest on March 31, 2024 provided that the Issuer's Compensation Committee has determined that Performance Condition No. 2 (as defined below) has been met; provided further that, in each case, the grantee will have been continuously a service provider from the date of grant through each such vesting date. Performance Condition No. 1 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2023 has exceeded $135 per share. Performance Condition No. 2 means that the average closing price per share of the Issuer's common stock in any 45 consecutive trading day period prior to March 15, 2024 has exceeded $170 per share.